An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Investigators from Shanghai, China, report responses above 90% by using levantinib and tislelizumab to treat patients with a form of renal cell carcinoma (RCC) driven by a mostly inherited mutation.

There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...

Unpacking your problems for an hour each week with a professional is being talked about for all the wrong reasons ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

The Medical University of South Carolina Health has established the Rena N. Grant Sickle Cell Center to help treat those ...

Background Treatment strategies for Crohn’s disease (CD) suppress diverse inflammatory pathways but many patients remain ...

The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.